Clinical trials: Hepatitis C Chronic
Liver Fibrosis Progression in Chronic Liver Disease
LIVER FIBROSIS PREVALENCE IN FRANCE
"Mortality related to complications of cirrhosis, (hemorrhage, hepatic insufficiency and primary liver cancer) is 15,000 per year in France.
- Trial name
- FIBROFRANCE (NCT01927133)
- Where
- France
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatitis C, Hemophilia
Pegasys® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus Infection
Hemophilic patients are a known high risk groups for acquiring the hepatitis C. The surveillance data from Ministry Of Health in IR.Iran had shown that 60% of them are infected with HCV infection.
- Trial name
- NCT00707772
- Testing
- PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)
- Where
- Iran
- Volunteers
- 400 people
- Sponsor
- Baqiyatallah Medical Sciences University
Hepatitis C, Chronic
Efficacy and Safety of Zoval (Sofosbuvir) and Ribavirin With or Without Interferon
Title Efficacy and Safety of Zoval (Sofosbuvir) and Ribavirin with or without Interferon among Pakistani Population: A real life trial Hepatitis Eradication Accuracy Trial of Sofosbuvir (HEATS) Study Design Endpoint…
- Trial name
- HEATS (NCT02804386)
- Testing
- Sofosbuvir
- Where
- Pakistan
- Volunteers
- 573 people
- Sponsor
- PharmEvo Pvt Ltd
Chronic Hepatitis C
PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C
The purpose of this study is to determine the safety and efficacy of peginterferon alfa-2a (PEG-2a) in combination with ribavirin (RV) and PEG-2a alone for the treatment of chronic hepatitis C virus (CHC) infection in children.
- Trial name
- NCT00100659
- Testing
- Pegylated Interferon/ribavirin
- Where
- 11 sites in United States
- Volunteers
- 114 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis C Virus Infection
Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study
The purpose of this study was to evaluate the efficacy and safety of co-administration of glecaprevir (ABT-493)/pibrentasvir (ABT 530) plus sofosbuvir (SOF) plus ribavirin (RBV) in hepatitis C virus (HCV) genotype (GT) 1 …
- Trial name
- MAGELLAN-3 (NCT02939989)
- Testing
- Sofosbuvir, Glecaprevir/Pibrentasvir, Ribavirin
- Where
- 26 sites in United States, Australia and 10 more
- Volunteers
- 33 people
- Sponsor
- AbbVie
Hepatitis C, Chronic
Impact of the Sustained Viral Response of Chronic Hepatitis c After Treatment With Direct Action Antivirals
The purpose of this study is to evaluate the evolution of liver injury with fibrosis data obtained using non-invasive serological markers in patients who achieved SVR after treatment with direct-acting antivirals.
- Trial name
- Hepatitis (NCT05062408)
- Where
- Spain
- Volunteers
- 321 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Chronic Hepatitis C
The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Chronic Hepatitis C
The efficacy of combination antiviral therapy for chronic hepatitis C is influenced by many factors. Important patient-specific factors include, age, gender, race, body weight.
- Trial name
- NCT01464008
- Testing
- Pegylated interferon alfa-2a and ribavirin
- Where
- China
- Volunteers
- 297 people
- Sponsor
- Beijing Ditan Hospital
Hepatitis C
Phase III Randomized Study of High Vs Standard Dose of Interferon Alfa for Chronic Hepatitis C
OBJECTIVES: I. Determine whether the initial response to interferon alfa (IFN-A) can be increased by starting at a dose of 5 MU three times a week in patients with chronic hepatitis C. II.
- Trial name
- NCT00004804
- Testing
- interferon alfa
- Volunteers
- 57 people
- Sponsor
- National Center for Research Resources (NCRR)
Hepatitis C Virus (HCV)
A Study of the Effectiveness and Clinical Practice Use of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Genotypes 1 to 6 in Russian Federation
The objective of this study is to assess the effectiveness of the glecaprevir/pibrentasvir (GLE/PIB) regimen in adolescent participants aged 12 to <18 years of age with chronic hepatitis C (CHC) in clinical practice in the…
- Trial name
- DETI-2 (NCT04189627)
- Where
- 8 sites in Russia
- Volunteers
- 99 people
- Sponsor
- AbbVie
HIV Infections, Sexually Transmitted Infection
User-friendly HIV Testing and Counseling Services
Multicenter cohort study of individuals reporting behavioral risks of HIV acquisition, recruited among those presenting for testing for HIV and other sexually transmitted infections.
- Conditions
- HIV Infections, Sexually Transmitted Infection, Hepatitis B, Chronic, Hepatitis C
- Trial name
- NCT04585165
- Where
- 6 sites in Thailand
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Institut de Recherche pour le Developpement
Hepatitis C, Chronic
Hansenula-Derived Pegylated-Interferon Alpha-2a in Egyptian Children With Chronic HCV
Egypt has the highest prevalence of hepatitis C virus infection in adults (up to 20%) and children (up to 5.5%). The major genotype (90%) is type 4.
- Trial name
- NCT02027493
- Testing
- Reiferon R, Ribavirin
- Where
- 3 sites in Egypt
- Volunteers
- 46 people
- Sponsor
- National Liver Institute, Egypt
Chronic Hepatitis C Virus
Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1
The main objective of this study is to evaluate the safety and effectiveness of paritaprevir/ritonavir/ombitasvir used for patients infected with HCV genotype 1 in daily practice in Japan.
- Trial name
- NCT02629172
- Where
- 388 sites in Japan
- Volunteers
- 3,043 people
- Sponsor
- AbbVie
Hepatitis C
History of Hepatitis C in Volunteer Blood Donors
Hepatitis C is a disease of the liver caused by the Hepatitis C Virus (HCV). Patients with hepatitis C may feel well and show no signs or symptoms of being ill.
- Trial name
- NCT00001982
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis C,Chronic Children, Only
Twelve Weeks Sofosbuvir/Daclatasvir in HCV Infected Children Aged 6-18 Years
Recently the era of direct-acting antiviral drugs for hepatitis C treatment has changed the world map of HCV. Results in adults are promising. FDA approved only two drugs in the pediatric age group 12 to 17 years.
- Trial name
- NCT07905989
- Testing
- Sofosbuvir/Daclatasvir
- Where
- Egypt
- Volunteers
- 42 people
- Sponsor
- National Liver Institute, Egypt
Liver Fibrosis
Anticoagulation in Liver Fibrosis in Patients With Hepatitis C Virus Infection
Patients who have been treated for hepatitis C virus (HCV) infection who have failed to respond to anti-viral treatment are often concerned about their ongoing liver disease and are therefore looking for alternative treatments…
- Trial name
- NCT00180674
- Testing
- Warfarin
- Where
- United Kingdom
- Volunteers
- 14 people
- Sponsor
- Imperial College London
Hepatitis C Genotype 4
Treatment of Egyptian Hepatitis C Genotype 4 Infected Children and Adolescents With Combined Ledipasvir/Sofosbuvir
This is an open, uncontrolled study of twenty-five chronic HCV infected patients carried out at Yassin Abdel Ghaffar Charity Center for Liver Disease and Research.
- Trial name
- NCT03743727
- Testing
- Combined therapy LDV and SOF
- Where
- Egypt
- Volunteers
- 25 people
- Sponsor
- Yassin Abdelghaffar Charity Center for Liver Disease and Research
Hepatitis C Virus Infection, Past or Present, Chronic Hepatitis c
Cross Sectional Survey on the Burden, Impacts and Causes of Hepatitis C Virus (HCV) Outbreak in South West Region in Burkina Faso
This study investigates hepatitis C virus (HCV) outbreak in South West general population in Burkina Faso with three specific objectives: estimate HCV prevalence in South West Region general population in 2019; identify factors…
- Trial name
- REVERSO (NCT04136405)
- Where
- Burkina Faso
- Volunteers
- 3,300 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis C Virus (HCV)
Efficacy Study Of Oral Glecaprevir/Pibrentasvir Tablet In Pediatric (12 Years and Older) And Adult Treatment-Naive Participants With Chronic Hepatitis C Genotypes 1 To 6 And Liver Cirrhosis
Hepatitis C Virus (HCV) infection is among the most common of all chronic liver diseases. HCV predominantly affects liver cells and causes the liver to become inflamed and damaged.
- Trial name
- EASY (NCT04352309)
- Where
- 6 sites in Russia
- Volunteers
- 99 people
- Sponsor
- AbbVie
Hepatitis C, Chronic
PegIntron Injection Surveillance Plan (Study P04123)
Surveillance will be conducted at digestive departments of internal medicine in university or general hospitals where participants with chronic hepatitis C are generally treated.
- Trial name
- NCT00723931
- Testing
- Peginterferon alfa-2b (SCH 54031)
- Volunteers
- 1,267 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)
The purpose of the study is to determine whether the combination of Daclatasvir (DCV), Asunaprevir (ASV), BMS-791325 and Sofosbuvir is effective and safe in treating Hepatitis-C virus.
- Trial name
- FOURward (NCT02175966)
- Testing
- DCV/ASV/BMS-791325, Ribavirin, Sofosbuvir
- Where
- 7 sites in United States
- Volunteers
- 35 people
- Sponsor
- Bristol-Myers Squibb